Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …

Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …

Background: It remains unclear whether the use of new oral anticoagulants, compared with
warfarin, is economically beneficial in Asian countries. Objective: The objective of this study …

Background: Warfarin has provided protection against cardioembolic stroke in the setting of
nonvalvular atrial fibrillation (NVAF) for the past 60 years. Dabigatran, the first oral direct …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

Background: Dabigatran was the first novel oral anticoagulant (OAC) approved in the US for
stroke risk reduction in patients with non-valvular atrial fibrillation (NVAF). The aim of this …